Introduction
============

Colon cancer is the most common type of tumor of the gastrointestinal tract, and ranks as the third highest cause of cancer-associated mortality worldwide ([@b1-ol-0-0-10730]). The etiology and pathogenesis of colon cancer are complex and are associated with various factors, such as diet- and lifestyle-associated genetic and epigenetic changes ([@b2-ol-0-0-10730]). Recent advances in the treatment of colon cancer have been reported, including surgery combined with chemotherapy, radiofrequency ablation or targeted therapy; however, the rate of postoperative recurrence remain at \~50%, leading to a poor overall survival (OS) for the patients with colon cancer ([@b3-ol-0-0-10730]). Therefore, there is an urgent need to identify novel biomarkers and potential therapeutic targets for this deadly disease ([@b4-ol-0-0-10730]).

Long non-coding RNAs (lncRNAs), which are \>200 nucleotides in length, have been reported to act as key regulators of various biological processes; the aberrant expression of lncRNAs are associated with several diseases, including cancer ([@b5-ol-0-0-10730]--[@b9-ol-0-0-10730]). Accumulating evidence has suggested that lncRNAs could serve as potential biomarkers for the early diagnosis, prognosis and prediction of metastasis for various types of malignancy ([@b10-ol-0-0-10730]--[@b15-ol-0-0-10730]).

In recent years, with advances in bioinformatics and interdisciplinary studies involving the development of a series of computational methods and software tools for the analysis of extensive biological data, numerous lncRNAs have been identified to be dysregulated in colon cancer. For instance, by a bioinformatic approach, a recent study classified Linc00659 as a novel oncogenic lncRNA involved in the tumorigenesis of colon cancer by modulating the progression of the cell cycle; downregulation of Linc00659 expression resulted in severe cell cycle arrest and enhanced the apoptosis of colon cancer cells ([@b16-ol-0-0-10730]). Similarly, based on bioinformatics analysis of The Cancer Genome Atlas (TCGA) and/or the Gene Expression Omnibus datasets, as well as subsequent experimental validation, metastasis-associated lung adenocarcinoma transcript 1 and small nuclear host gene 1 have been recently identified to be oncogenic lncRNAs, which may serve as potential diagnostic and therapeutic targets in colorectal cancer (CRC) ([@b17-ol-0-0-10730]--[@b20-ol-0-0-10730]). These results suggest the potential clinical value of lncRNAs in CRC; however, the lncRNAs associated with the prognosis and survival of patients, as well as their biological roles, require further investigation.

Therefore, the present study aimed to identify the key lncRNAs associated with their prognostic and biological roles using a comprehensive bioinformatics process. The gene expression datasets downloaded from The Cancer Genome Atlas (TCGA) database, which includes the corresponding survival and Tumor-Node-Metastasis (TNM) stage ([@b21-ol-0-0-10730]) status of patients with CRC, were utilized to construct a prognostic prediction system.

Materials and methods
=====================

### TCGA CRC data mining and screening

The level 3 normalized lncRNA expression data of CRC, CRC gene expression data and corresponding clinical data were obtained from the TCGA database (<https://cancergenome.nih.gov>). The expression profiling platform RNA-seqv2 was used. No further normalizations were applied to the level 3 lncRNA expression profile data. A total of 521 samples were obtained, of which 480 were CRC tissues and 41 were adjacent normal tissues. The lncRNA expression profile of tumor and normal tissues was determined to screen for differentially expressed lncRNAs using edgeR (<http://www.bioconductor.org/packages/release/bioc/html/edgeR.html>; R software; version 3.4.2; Bell Laboratories) with thresholds of \|log2\[fold-change (FC)\]\|\>2.0 and adjusted P-value \[false discovery rate (FDR)\]\<0.05. A volcano plot was generated using theplot function in R (<https://www.rdocumentation.org/packages/graphics/versions/3.6.0/topics/pl>; R software; version 3.4.2; Bell Laboratories).

### Survival analysis

Kaplan-Meier analysis followed by a log-rank test was performed to assess the OS between low- and high-lncRNA expression groups using the R package 'survival' (<https://cran.r-project.org/web/packages/survival/index.html>; R software; version 3.4.2; Bell Laboratories). The Kruskal-Wallis test was used to evaluate the association between tumor stage. The staging system of colon cancer using UICC/AJCC (7th edition) ([@b21-ol-0-0-10730]), and the lncRNAs that were significantly associated with OS. Additionally, univariate and multivariate Cox regression analyses were used to evaluate the association between the expression levels of lncRNAs and the OS of patients with CRC, and to identify independent prognostic values of lncRNAs. P\<0.05 was considered to indicate a statistically significant difference.

### Analysis of co-expressed protein-coding genes (PCGs)

To determine the association between lncRNAs and co-expressed PCGs, the Pearson correlation coefficients (r) of the lncRNAs and PCGs were calculated using the cor.test function in R. The PCGs with \|r\|\>0.4 and P\<0.001 were considered as lncRNA-associated PCGs.

### Functional and pathway enrichment analyses

The identified co-expressed PCGs were further investigated using clusterProfiler R package (<http://www.bioconductor.org/packages/release/bioc/html/clusterProfiler.html>; R software; version 3.4.2; Bell Laboratories), including functional Gene Ontology (GO) ([@b22-ol-0-0-10730]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b23-ol-0-0-10730]) pathway enrichment analyses. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of significantly differentially expressed lncRNAs in CRC

In a preliminary screening, the data of 480 CRC and 41 adjacent normal colorectal mucosal tissues were extracted from the symbol matrix. A total of 1,180 significant differentially expressed lncRNAs were identified with \|logFC\|\>2 and FDR\<0.05, of which 916 were upregulated and 264 were downregulated. A volcano plot of the identified lncRNAs was constructed ([Fig. 1](#f1-ol-0-0-10730){ref-type="fig"}). The top 10 upregulated and downregulated lncRNAs are presented in [Tables I](#tI-ol-0-0-10730){ref-type="table"} and [II](#tII-ol-0-0-10730){ref-type="table"}.

### Analysis of significant differentially expressed lncRNAs in CRC samples associated with OS and pathological stages

To investigate the association between lncRNA expression and OS, the expression profile of the 1,180 lncRNAs in tumor samples were determined, of which 56 lncRNAs were associated with OS, as determined by Kaplan-Meier analysis ([Table III](#tIII-ol-0-0-10730){ref-type="table"}). The top 10 lncRNAs significantly associated with OS (P\<0.05) were RP11-108K3.2, RP11-815M8.1, LINC01836, AC079612.1, LINC01354, RBAKDN, RP11-400N13.2, RP1-142L7.9, AFAP1-AS1 and LINC01655 ([Fig. 2](#f2-ol-0-0-10730){ref-type="fig"}).

The association between clinical stages (UICC/AJCC 7th Edition) ([@b21-ol-0-0-10730]) and the 56 lncRNAs associated with OS was determined via a Kruskal-Wallis test. The results demonstrated that 7 lncRNAs were identified as key lncRNAs associated with the Tumor-Node-Metastasis (TNM) stages of colon cancer, including DNAH17-AS1, RP11-429J17.5, RP11-742B18.1, RP11-400N13.2, LL22NC03-N14H11.1, LINC01836 and HOTAIR ([Table IV](#tIV-ol-0-0-10730){ref-type="table"}; [Fig. 3](#f3-ol-0-0-10730){ref-type="fig"}). The detailed information of the patients at each TNM stage is presented in [Table SI](#SD2-ol-0-0-10730){ref-type="supplementary-material"}. Notably, these 7 lncRNAs were upregulated in colon cancer tissues compared with adjacent normal tissues, suggesting that they may serve a tumorigenic role in the initiation and progression of CRC.

### Identification of independent prognostic lncRNAs in CRC

In order to detect potential independent prognostic lncRNAs in patients with CRC, univariate and multivariate Cox regression analyses of these 7 lncRNAs associated with TNM stage were performed. The association between the expression levels of lncRNAs and the OS of patients with colon cancer was explored using the R package 'survival'; 2 lncRNAs, DNAH17-AS1 and RP11-400N13.2, were identified to be independent prognostic factors for OS in patients with CRC (P\<0.05; [Tables V](#tV-ol-0-0-10730){ref-type="table"} and [VI](#tVI-ol-0-0-10730){ref-type="table"}).

### Analyses of PCGs co-expressed with lncRNAs DNAH17-AS1 and RP11-400N13.2

Analysis of the PCGs co-expressed with DNAH17-AS1 and RP11-400N13.2 was conducted using the cor.test function with thresholds of \|r\|\>0.4 and P\<0.001. The results revealed that 1,048 PCGs were co-expressed with DNAH17-AS1 ([Fig. 4A](#f4-ol-0-0-10730){ref-type="fig"}). Due to a large number of PCGs in DNAH17-AS1, only the top 100 genes with a lower P-value were presented in [Fig. 4A](#f4-ol-0-0-10730){ref-type="fig"}. A total of 126 PCGs co-expressed with RP11-400N13.2 ([Fig. 4B](#f4-ol-0-0-10730){ref-type="fig"}). The top 10 significant PCGs that were identified to be co-expressed with the 2 lncRNAs are listed in [Table VII](#tVII-ol-0-0-10730){ref-type="table"}.

### GO and KEGG enrichment analyses of the PCGs co-expressed with DNAH17-AS1 and RP11-400N13.2

To further investigate the potential roles of the two independent prognostic lncRNAs identified in the present study, functional enrichment analyses for their co-expressed PCGs were performed using the clusterProfiler R package. The results indicated that the PCGs co-expressed with DNAH17-AS1 were mainly enriched in 'G-protein coupled receptor signaling pathway', 'detection of chemical stimulus involved in sensory perception of smell', 'integral component of membrane', 'integral component of plasma membrane', 'G-protein coupled receptor activity' and 'olfactory receptor activity'. Collectively, these PCGs were associated with G-protein coupling and cell membrane function ([Fig. 5A](#f5-ol-0-0-10730){ref-type="fig"}). Additionally, the PCGs co-expressed with RP11-400N13.2 were mainly enriched in 'G-protein coupled receptor signaling pathway', 'G-protein coupled receptor activity', 'spermatogenesis', 'negative regulation of endopeptidase activity' and 'endopeptidase inhibitor activity', which are involved in G-protein coupling and endopeptidase function ([Fig. 5B](#f5-ol-0-0-10730){ref-type="fig"}). Functional enrichment analysis revealed a high level of involvement of the associated PCGs inG-protein coupling, which suggested a crucial biological function of DNAH17-AS1 and RP11-400N13.2. The detailed information of the genes with G-protein-associated functions co-expressed with DNAH17-AS1 and RP11-400N13.2 is presented in [Table SII](#SD3-ol-0-0-10730){ref-type="supplementary-material"}. A total of 3 of these genes, 5′-hydroxytryptamine receptor 6, melanocortin 5 receptor and prokineticin receptor 2, were significantly associated with OS (P\<0.05; [Fig. S1](#SD1-ol-0-0-10730){ref-type="supplementary-material"}).

KEGG pathway enrichment analysis of the PCGs co-expressed with the two independent prognostic lncRNAs was performed using clusterProfiler package in R with a threshold of P\<0.05. The results revealed that the PCGs co-expressed with DNAH17-AS1 were involved in seven pathways, including 'olfactory transduction', 'neuroactive ligand-receptor interaction', 'phototransduction', 'nicotine addiction', 'cocaine addiction', 'collecting duct acid secretion' and 'signaling pathways regulating pluripotency of stem cells' ([Fig. 6](#f6-ol-0-0-10730){ref-type="fig"}). This result provided novel insights into the potential associations between these pathways and CRC, which warrant further investigation. Of note, P\>0.05 was reported for the enriched pathways of the PCGs co-expressed with RP11-400N13.2.

Discussion
==========

In the present study, *in silico* analysis revealed 1,180 significantly differentially expressed lncRNAs that were associated with colorectal cancer, of which 56 and 7 genes were significantly associated with OS and TNM stage, respectively. Subsequent univariate and multivariate Cox regression analyses indicated that 2 of the 7 lncRNAs, DNAH17-AS1 and RP11-400N13.2, may be independent prognostic lncRNAs for the OS of patients with colorectal cancer.

To the best of our knowledge, lncRNAs DNAH17-AS1 and RP11-400N13.2 have not been previously associated with colon cancer; however, a missense variant p.R3953Y of DNAH17, the related protein of DNAH17-AS1, was reported in undifferentiated embryonal sarcoma of the liver in a child ([@b24-ol-0-0-10730]). Additionally, p.R3953 of DNAH17 exhibited a high level of conservation among a variety of species, suggesting that this allele may be an important locus associated with protein function ([@b24-ol-0-0-10730]). A recent study revealed the mutational profile and a distinct mutation signature of T:A\>A:T transversion in early-stage hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) infection; thus, as a key gene of the mutational profile, DNAH17 was proposed to serve an important role in the HBV-mediated transformation of liver cells ([@b25-ol-0-0-10730]). Additionally, the hypomethylation status of DNAH17 has been reported in HCC, which is associated with several clinical characteristics and may serve as a potential biomarker of tumor thrombosis in patients with HCC ([@b26-ol-0-0-10730]). In the present study, the lncRNA expression level of DNAH17-AS1 in CRC samples was analyzed and compared with that in normal samples; however, the expression level and the methylation status of DNAH17 were not analyzed. Although the expression level of DNAH17, as well as its methylation status in CRC samples, may be informative to determine the role of DNAH17 in CRC, this was beyond the scope of the present study. Therefore, relevant studies will be performed in the future.

A limited number of studies have investigated RP11-400N13.2; however, other RP11 family members have been frequently reported to be dysregulated in CRC. RP11-708H21.4, an RP11 family lncRNA located in the 17q21 gene desert region, was proposed to serve a suppressive role in the tumorigenesis of colorectal cancer and act as a novel powerful diagnostic biomarker, as well as a therapeutic target for the treatment of CRC ([@b27-ol-0-0-10730]). The expression levels of RP11-462C24.1, another member of the RP11 family, were determined to be significantly correlated with distant metastasis in patients with CRC, and may serve as a potential prognostic marker for such patients ([@b28-ol-0-0-10730]). Additionally, the dysregulation of RP11 family members has been reported to be involved in other types of cancer. For instance, a recent study revealed that overexpression of lncRNA RP11-190D6.2 inhibited the proliferation, migration and invasion of epithelial ovarian cancer (EOC) cells and may be considered a novel biomarker and therapeutic target for EOC ([@b29-ol-0-0-10730]). Furthermore, lncRNA RP11-436H11.5 was identified to function as a competing endogenous RNA to promote the proliferation and invasion of renal cell carcinoma (RCC) cells, which suggests that RP11-436H11.5 may be a potential therapeutic target to suppress RCC tumorigenesis ([@b30-ol-0-0-10730]). Collectively, the RP11 family of lncRNAs serve important roles in carcinogenesis and may be used as potential diagnostic and prognostic biomarkers for various types of cancer.

Following the identification of two independent prognostic lncRNAs in colorectal cancer, the co-expressed PCGs were analyzed, and stepwise GO and KEGG enrichment analyses were conducted to determine the potential biological functions of these lncRNAs associated with CRC and the signaling pathways involved. The results of the functional enrichment analysis of DNAH17-AS1 and RP11-400N13.2 differed; however, these lncRNAs were determined to possess similar G-protein coupling-associated functions. G-protein coupled receptors have been previously reported to be associated with CRC tumorigenesis ([@b31-ol-0-0-10730]--[@b34-ol-0-0-10730]). For example, the G-protein coupled receptor GPR55 may promote tumor progression by acting as an pro-oncogenic factor in CRC ([@b31-ol-0-0-10730]). In addition, GPR55 has been proposed to be involved in the migration of CRC cells and may serve as a potential target for the prevention of metastasis ([@b32-ol-0-0-10730]). On the contrary, orexin receptor type 1 and cholecystokinin A receptor, which belong to family A of the G-protein coupled receptors, serve opposing roles in the regulation of HT-29 CRC cell migration, but have also been reported to be involved in the pathogenesis of CRC metastasis ([@b33-ol-0-0-10730]). Furthermore, a recent study revealed that GPR109A, a G-protein coupled receptor for short-chain fatty acids, was silenced in CRC cells ([@b34-ol-0-0-10730]). In addition, the host immune system may employ interferon γ to counteract methylation-mediated silencing of GPR109A as a mechanism to suppress tumor development ([@b34-ol-0-0-10730]). Therefore, G-protein coupled receptors maybe associated with the carcinogenesis and metastasis of CRC; the roles of DNAH17-AS1 and RP11-400N13.2 in CRC, which may be mediated by these receptors, require further investigation.

In the present study, DNAH17-AS1 and RP11-400N13.2 were identified as potential independent prognostic lncRNAs for OS in patients with CRC. Further bioinformatics analyses revealed that these 2 lncRNAs may serve a pro-oncogenic role in CRC via G-protein coupling-related functions. Therefore, DNAH17-AS1 and RP11-400N13.2 may serve as prognostic biomarkers for CRC in the future. The detailed methodology of the present study is presented in [Fig. S2](#SD1-ol-0-0-10730){ref-type="supplementary-material"}.
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![Volcano plot of significantly differentially expressed lncRNAs associated with colorectal cancer. Red, green and black dots represent upregulated, downregulated and non-differentially expressed lncRNAs, respectively. lncRNA, long non-coding RNA; FC, fold-change; FDR, false discovery rate.](ol-18-04-3705-g00){#f1-ol-0-0-10730}

![Top 10 lncRNAs associated with overall survival derived from 1,180 significantly differentially expressed genes. Patients were divided into high and low expression groups according to the median value of all patients. The data of the top 10 of the 56 lncRNAs are presented. lncRNA, long non-coding RNA.](ol-18-04-3705-g01){#f2-ol-0-0-10730}

![A total of 7 lncRNAsare significantly associated with the clinical stages of patients with colorectal cancer. The horizontal axis represents the clinical stage, whereas the vertical axis represents the expression levels of 7 lncRNAs that were significantly associated with the clinical stages of patients with colorectal cancer. lncRNA, long noncoding RNA.](ol-18-04-3705-g02){#f3-ol-0-0-10730}

###### 

Interactions between two long non-coding RNAs and co-expressed PCGs. (A) DNAH17-AS1 was co-expressed with 1,048 PCGs. (B) RP11-400N13.2 was co-expressed with 126 PCGs. PCGs, protein-coding genes.
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###### 

GO enrichment analysis maps of co-expressed PCGs associated with certain long non-coding RNAs. (A) The most enriched GO terms of PCGs co-expressed with DNAH17-AS1. (B) The most enriched GO terms of PCGs co-expressed with RP11-400N13.2. The colors of the columns represent the different types of terms. GO, Gene Ontology; PCGs, protein-coding genes; BP, biological process; CC, cellular component; MF, molecular function.
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![KEGG enrichment analysis of PCGs co-expressed with DNAH17-AS1. The size of the dots indicates the number of enriched PCGs; the color of the dots represents the degree of significance based on the P-value. KEGG, Kyoto Encyclopedia of Genes and Genomes; PCGs, protein-coding genes.](ol-18-04-3705-g07){#f6-ol-0-0-10730}

###### 

Top 10 upregulated lncRNAs with significantly different expression between tumor and normal tissues in The Cancer Genome Atlas colon cancer data.

  lncRNA          Ensembl_Gene_ID   logFC   P-value        FDR
  --------------- ----------------- ------- -------------- --------------
  PVT1            ENSG00000249859   2.58    1.70×10^−67^   4.23×10^−65^
  CCAT1           ENSG00000247844   4.47    1.68×10^−59^   2.51×10^−57^
  BLACAT1         ENSG00000281406   5.12    3.88×10^−59^   5.59×10^−57^
  LINC02163       ENSG00000251026   7.08    1.19×10^−54^   1.37×10^−52^
  CRNDE           ENSG00000245694   4.58    1.30×10^−52^   1.31×10^−50^
  MAFG-AS1        ENSG00000265688   2.88    7.82×10^−51^   7.51×10^−49^
  RP5-884M6.1     ENSG00000228742   6.31    1.04×10^−50^   9.69×10^−49^
  CASC19          ENSG00000254166   4.51    3.30×10^−50^   3.02×10^−48^
  RP5-1120P11.1   ENSG00000237686   4.41    7.64×10^−50^   6.65×10^−48^
  AC007128.1      ENSG00000229970   4.48    2.64×10^−48^   2.17×10^−46^

lncRNA, long non-coding RNA; FC, fold-change; FDR, false discovery rate.

###### 

Top 10 downregulated lncRNAs with significantly different expression between tumor and normal tissues in The Cancer Genome Atlas colon cancer data.

  lncRNA            Ensembl_Gene_ID   logFC   P-value         FDR
  ----------------- ----------------- ------- --------------- ---------------
  XXbac-B476C20.9   ENSG00000225335   −2.72   2.14×10^−173^   1.60×10^−169^
  CDKN2B-AS1        ENSG00000240498   −5.21   9.05×10^−140^   3.39×10^−136^
  LINC01645         ENSG00000224968   −4.60   6.90×10^−127^   1.72×10^−123^
  PP7080            ENSG00000188242   −3.48   3.24×10^−124^   6.07×10^−121^
  XXyac-YM21GA2.7   ENSG00000214888   −5.69   7.06×10^−120^   1.06×10^−116^
  RP11-1090M7.1     ENSG00000265489   −4.48   1.49×10^−116^   1.85×10^−113^
  RP11-396O20.2     ENSG00000254645   −5.01   1.71×10^−114^   1.83×10^−111^
  AC007182.6        ENSG00000224721   −4.67   4.65×10^−108^   4.35×10^−105^
  AC106869.2        ENSG00000226087   −4.18   2.71×10^−105^   2.25×10^−102^
  LINC00682         ENSG00000245870   −4.55   1.18×10^−96^    8.82×10^−94^

lncRNA, long non-coding RNA; FC, fold-change; FDR, false discovery rate.

###### 

lncRNAs significantly associated with OS.

  lncRNA              Ensembl_Gene_ID   P-value
  ------------------- ----------------- ----------------
  RP11-108K3.2        ENSG00000259306   1.98646×10^−5^
  RP11-815M8.1        ENSG00000238042   2.78454×10^−5^
  LINC01836           ENSG00000267530   0.000256940
  AC079612.1          ENSG00000196758   0.000535749
  LINC01354           ENSG00000231768   0.000985613
  RBAKDN              ENSG00000273313   0.001143877
  RP11-400N13.2       ENSG00000228437   0.002268513
  RP1-142L7.9         ENSG00000270661   0.003700521
  AFAP1-AS1           ENSG00000272620   0.004000305
  LINC01655           ENSG00000227925   0.004380952
  RP11-10A14.5        ENSG00000248538   0.004693149
  RP11-384P7.7        ENSG00000260947   0.004845978
  RP11-434D9.2        ENSG00000249894   0.005561553
  RP11-742B18.1       ENSG00000249001   0.007363036
  CTC-327F10.4        ENSG00000251320   0.008786437
  AC064834.1          ENSG00000224099   0.00890189
  ARHGEF26-AS1        ENSG00000243069   0.008966797
  RP3-380B8.4         ENSG00000233064   0.009485845
  LINC01829           ENSG00000236780   0.009974597
  GAS1RR              ENSG00000226237   0.013908392
  RP11-84A19.4        ENSG00000269967   0.014180465
  LINC02043           ENSG00000232233   0.016339686
  LINC00922           ENSG00000261742   0.016854765
  RP11-278L15.2       ENSG00000243885   0.017325027
  RP1-122P22.4        ENSG00000268628   0.018507105
  RP11-366L20.2       ENSG00000197301   0.019632443
  DUXAP8              ENSG00000206195   0.020361403
  CTB-181H17.1        ENSG00000272219   0.020685373
  MIR31HG             ENSG00000171889   0.021365649
  AC012531.25         ENSG00000260597   0.023942649
  FOXD3-AS1           ENSG00000230798   0.024144909
  AC007128.1          ENSG00000229970   0.027145232
  DNAH17-AS1          ENSG00000267432   0.02735923
  LINC01833           ENSG00000259439   0.027941465
  RP11-429J17.5       ENSG00000254548   0.028089082
  LL22NC03-N14H11.1   ENSG00000272872   0.031532618
  RP1-79C4.4          ENSG00000271811   0.031571197
  CTB-186G2.4         ENSG00000267375   0.031679272
  RP11-114H23.2       ENSG00000258088   0.033221364
  LINC00484           ENSG00000229694   0.035515205
  RP1-29C18.10        ENSG00000212939   0.035961207
  AC073326.3          ENSG00000228540   0.036298277
  RP11-126H7.4        ENSG00000204049   0.036449014
  CTD-2619J13.13      ENSG00000268307   0.037145687
  LINC01748           ENSG00000226476   0.038383393
  RP11-532F6.3        ENSG00000272463   0.042708274
  RP11-728G15.1       ENSG00000256008   0.043149989
  LINC01060           ENSG00000249378   0.045508319
  KCNQ1OT1            ENSG00000269821   0.045529181
  LINC01996           ENSG00000261863   0.046591159
  ELFN1-AS1           ENSG00000236081   0.046625182
  HOTAIR              ENSG00000228630   0.047908786
  LINC00461           ENSG00000245526   0.04796558
  CTD-2600O9.1        ENSG00000187185   0.048650792
  LEF1-AS1            ENSG00000232021   0.049375626
  FLJ16779            ENSG00000275620   0.049920309

lncRNA, long non-coding RNA.

###### 

lncRNAs significantly associated with tumor clinical stage.

  lncRNA              Ensembl_Gene_ID   P-value
  ------------------- ----------------- -------------
  FLJ16779            ENSG00000275620   0.049920309
  DNAH17-AS1          ENSG00000267432   6.42×10^−5^
  RP11-429J17.5       ENSG00000254548   0.000628536
  RP11-742B18.1       ENSG00000249001   0.00141941
  RP11-400N13.2       ENSG00000228437   0.003179863
  LL22NC03-N14H11.1   ENSG00000272872   0.005376623
  LINC01836           ENSG00000267530   0.011461646
  HOTAIR              ENSG00000228630   0.013000989

lncRNA, long non-coding RNA.

###### 

Cox regression analyses of the association between DNAH17-AS1 and patient clinicopathological characteristics.

               Univariate     Multivariate                                                                      
  ------------ -------------- -------------- ------------- ------------- ------------- ---------- ------------- -------------
  Age, years   1.54×10^−2^    1.024705       1.00467006    1.045139527   8.62×10^−5^   1.043293   1.021452741   1.065600322
  Sex          8.11×10^−1^    1.055993       0.675320904   1.651244946   5.15×10^−1^   0.859753   0.545233986   1.355701712
  Stage        4.32×10^−10^   2.260538       1.749817646   2.92032165    3.09×10^−1^   1.481753   0.693752964   3.164805106
  T            5.85×10^−6^    2.842169       1.809061684   4.465257511   4.32×10^−2^   1.753715   1.017244601   3.023378521
  M            6.75×10^−10^   4.348202       2.726493071   6.934496948   3.83×10^−1^   1.584756   0.562533031   4.464537953
  N            1.29×10^−7^    2.014039       1.553071957   2.611824311   2.84×10^−1^   1.281519   0.813788046   2.01808327
  DNAH17-AS1   1.17×10^−3^    56.08087       4.924770723   638.6214937   1.61×10^−2^   29.59342   1.872773849   467.6327355

HR, hazard ratio; HR (lower 0.95), hazard ratio (lower 95% CI); HR (upper 0.95), hazard ratio (upper 95%CI); T, tumor; N, node; M, metastasis.

###### 

Cox regression analyses of the association between RP11-400N13.2 and patient clinicopathological characteristics.

                  Univariate     Multivariate                                                                      
  --------------- -------------- -------------- ------------- ------------- ------------- ---------- ------------- -------------
  Age, years      1.54×10^−2^    1.024705       1.00467006    1.045139527   3.70×10^−4^   1.03741    1.016647195   1.058596272
  Sex             8.11×10^−1^    1.055993       0.675320904   1.651244946   7.37×10^−1^   0.925432   0.588464244   1.455355124
  Stage           4.32×10^−10^   2.260538       1.749817646   2.92032165    2.61×10^−1^   1.54623    0.722569696   3.308782317
  T               5.85×10^−6^    2.842169       1.809061684   4.465257511   3.02×10^−2^   1.842378   1.059948791   3.202377507
  M               6.75×10^−10^   4.348202       2.726493071   6.934496948   3.49×10^−1^   1.628719   0.586703577   4.521408077
  N               1.29×10^−7^    2.014039       1.553071957   2.611824311   4.82×10^−1^   1.181526   0.741699234   1.882169148
  RP11-400N13.2   2.49×10^−4^    1.14629        1.065532018   1.233169628   6.46×10^−3^   1.117075   1.031523289   1.209722556

HR, hazard ratio; HR (lower 0.95), hazard ratio (lower 95% CI); HR (upper 0.95), hazard ratio (upper 95% CI); T, tumor stage; N, node stage; M, metastasis stage.

###### 

Co-expression analyses between DNAH17-AS1 and RP11-400N13.2 and the top 10 significant protein-coding genes.

  A, Genes co-expressed with DNAH17-AS1                                                                                      
  ---------------------------------------------- --------------------- ----------------------------------------------------- --------------
  DNAH17                                         ENSG00000187775       0.656                                                 2.73×10^−65^
  SSPO                                           ENSG00000197558       0.564                                                 4.89×10^−45^
  TPTE                                           ENSG00000274391       0.505                                                 4.31×10^−35^
  DPPA2                                          ENSG00000163530       0.473                                                 1.96×10^−30^
  GPR179                                         ENSG00000277399       0.473                                                 2.22×10^−30^
  RP11-505K9.4                                   ENSG00000260300       0.454                                                 8.07×10^−28^
  CFAP74                                         ENSG00000142609       0.453                                                 1.15×10^−27^
  POLG2                                          ENSG00000256525       0.451                                                 1.99×10^−27^
  KIF6                                           ENSG00000164627       0.449                                                 3.41×10^−27^
  STKLD1                                         ENSG00000198870       0.445                                                 9.44×10^−27^
                                                                                                                             
  **B, Genes co-expressed with RP11-400N13.2**                                                                               
                                                                                                                             
  **Co-expressed gene**                          **Ensembl_Gene_ID**   **r^[a](#tfn7-ol-0-0-10730){ref-type="table-fn"}^**   **P-value**
                                                                                                                             
  RP11-371E8.4                                   ENSG00000259066       0.439                                                 5.20×10^−26^
  RP11-507M3.1                                   ENSG00000276087       0.438                                                 8.64×10^−26^
  HIST3H3                                        ENSG00000168148       0.428                                                 1.26×10^−24^
  RP4-809F18.1                                   ENSG00000255595       0.428                                                 1.34×10^−24^
  OPRPN                                          ENSG00000171199       0.426                                                 2.51×10^−24^
  RP11-385D13.1                                  ENSG00000251537       0.423                                                 4.79×10^−24^
  OR52B2                                         ENSG00000255307       0.422                                                 5.87×10^−24^
  OR52B6                                         ENSG00000187747       0.422                                                 7.24×10^−24^
  OR2AG2                                         ENSG00000188124       0.401                                                 1.44×10^−21^
  BDNF                                           ENSG00000176697       0.397                                                 3.93×10^−21^

Pearson\'s correlation coefficient.

[^1]: Contributed equally
